Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today's filing with the S.E.C. is a real barn burner that knocked my socks off! They pull no punches as they lay out where they are at and where they plan to go! This is probably the basis of the presentation they are giving on Monday after the market closes. Check next message for link due to technical issues.
Listed here are three interesting links related to the proposed Phase 2 study to test MYMD-1 against Covid-19 induced depression. The 1st indicates that this study will begin in 2021's 1st quarter. The 2nd indicates that this study will begin in 2021's 2nd quarter, and the 3rd indicates that this same study will begin in 2021's 4th quarter.
https://www.bioworld.com/articles/500127-mymd-heads-to-nasdaq-via-reverse-merger-with-akers-biosciences
https://www.businesswire.com/news/home/20210413005702/en/
https://www.psychologytoday.com/us/blog/normal-is-overrated/202105/the-coming-epidemic-covid-19-associated-depression
Comments welcome!
Another quote from the Adam Kaplin article.
"One such therapy is MYMD-1, an immunometabolic modulator that is the subject of an upcoming Phase 2 trial to treat immune-mediated depression in COVID-19 patients. The trial is expected to be launched in the last quarter of 2021."
Last Fall they told us this trial was due to begin in 2021's 1st quarter, along with the Sarcopenia study. While I fully appreciate Dr. Adam Kaplin laying it all out there in this article, I do not appreciate a 6 month delay in this trial. It indicates that the company is not in control of its own destiny, or they are "operating on a shoestring".
From my experience, when a company begins a Phase 2 human study it issues a news release, which may even be required by the SEC.
In a Phase 2 study all participants are given the trial drug, and results are tabulated to measure its impact on the condition being trialed. If the results are sufficient a Phase 3 study may begin in which only 1/2 of the participants will receive the drug with the rest receiving a placebo.
Hope you are absolutely correct, but we have yet to begin the 1st human study after all these years!
This was newly added to MyMD website.
https://www.mymd.com/news/future-immunotherapies-for-multiple-sclerosis
MNMD is extremely more active as a message board than is MYMD!
Does this mean that MYMD has yet to be discovered by the MARKET.
There has never been a reason given for the switch from anatabine to isomyosmine, but in a comparative study isomyosmine had the greatest impact on the reduction of MOA-a and MOA-b.
My personal feeling was that they were just fleeing the negativity surrounding anatabine as well as the financial crisis of the share issuance to pay for studies!
leifsmith
"The MyMD-1 molecule may turn out to be of surprisingly great importance."
That appears to be the case, which makes one wonder why it is such a well kept secret.
SEAN
It's a tough read, and MYMD already has a patent!
Method of treating coronavirus
Patent number: 10918633
Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
Type: Grant
Filed: February 17, 2020
Date of Patent: February 16, 2021
Assignee: MyMD Pharmaceuticals, Inc.
Inventor: Jonnie R. Williams
Seems like I am talking to myself!
"RELATED: Gut bacteria point to novel strategies for combating asthma, COVID-19
The EMBL team started by creating 3D tissue models, or organoids, of the human gut. The models allowed them to determine that a particular subpopulation of cells called enterocytes are most affected by SARS-CoV-2.
They used single-cell RNA sequencing to track cell activity as the disease progressed, observing how the enterocytes triggered a response from the immune system by scrutinizing the activity of 12 genes.
The researchers were surprised to discover that the enterocytes most affected by the virus did not display high levels of ACE2, a cell-surface receptor that has previously been fingered as a culprit in causing COVID-19 infection. Furthermore, they found that infected gut cells mounted a pro-inflammatory response to the virus by pumping up levels of the transcription factor NFkB and the cytokine TNF."
Does the last sentence sound like MYMD-1 could do the job!
Interesting to note that DR Scott Freeman, a co-founder of Mind Medicine, (MNMD) is on the newly formed MyMD advisory board. Would very much like to see the sale of SUPERA-CBD to MNMD in exchange for a suitable number of shares of MNMD. Comments welcomed!
Looks like Craig Eagle might have been an investor in the private MyMD!
MindMed is going crazy on the Breakout Boards!
https://investorshub.advfn.com/boards/breakoutboards.aspx
Sorry, that was "sheer" genius!
The choice of the name MyMD was shear genius to the point of using a lower case "y" so that it reads "my doctor" when you look at it! You see it once, you remember it!
What MyMD desperately needs at this time are the human studies! The 1st quarter has passed with neither the Covid 19 depression study, nor the Sarcopenia study beginning as expected!
Neither of these studies is butting heads with other pharmaceutical companies as they are underserved areas, so they should proceed without rattling the cage. However, I assume that the pharmas are aware that MyMD is planning further studies such as Rheumatoid Arthritis, Multiple Sclerosis, and Type 2 Diabetes which may cause them to make life as difficult for MyMD as they legally can !!!!!
Thanks to whoever for the MyMD board. Here's to their outstanding success !!!!!
Extremely reasonable!!
When I said "Fasten your seat belts!", I was thinking "UP" not "DOWN"!
Today's action sure didn't reflect the last 2 days news releases!
WHAT HATH JONNIE WROUGHT !! I am blown away by the quality of this Scientific Discovery Board. It not only includes a healthy number of Johns Hopkins doctors, but also includes MINDMED and Eurofins Discovery.
Hopefully, MyMD Pharmaceuticals will become a public reality by the end of this week, and we can begin to share this awesome story much more widely than has been the case up to now.
Fasten your seat belts!
Someone just had to have 429,140 shares @ .005 !!!!!
Hard to believe! On 03/11/21 Jonnie and friends created yet another FL private company, this one called Arica Pharmaceuticals. Beginning to look like they are creating a company for each potential application of the isomyosmine and Supera families!
From a competitive point of view I see Jonnie as being ahead because he is ready to begin significant Phase 2 studies, and has chosen company and product names (MyMD Pharmaceuticals and MYMD-1) that are easily recognized and remembered.
What's going on here!!!!!!!
Those who are serious about MyMD Pharma should take a look at CohBar. (CWBR) Looks like it could be direct competition for MyMD. They are making many of the same claims as MyMD makes for MYMD-1.
Here is the latest website for MyMD for anyone who has not seen it. Contains a thorough explanation of what MyMD is all about!
https://www.mymd.com/
As has been revealed, Supera Pharma will be purchased by MyMD Pharma just before the final closing of the merger, for nearly 34 million MyMD Pharma shares, thus becoming an integral part of the new company. We have also become aware that a new private corporation was formed in FL this year under the name Nemo Life Sciences Inc., whose principal address is the suite in the Rangos Life Sciences Bldg on the Johns Hopkins campus where MyMD Pharmrceuticals is now located. A search of the internet indicated that NEMO is an integral part of the process of bone replacement and repair.
If that isn't enough, I have learned that another 10 (ten) private companies have been formed in FL this year by Jonnie and associates, all of which have as their principal address the same suite in Baltimore that MyMD Pharma occupies! They are,
PSYCHEDELX INC DOPAMYNE INC OXYGENE INC MIRAVID INC
ICENE INC KETAMIR INC COTIMINE INC SETACYBIN INC
REVLIMIR INC NYME INC
Can't seem to get it to open, but it is on page 166 in the S4 submitted to the SEC.
Since MyMD has not yet announced any human studies to discuss, I thought it might be helpful to take a look at the proposed MILESTONE PAYMENTS in the merger agreement. It's difficult to grasp and seems to result in as many questions as it answers. The current market cap of AKER is close to 60 million. Attached is the Milestone Payment Agreement.
file:///C:/Users/rondu/OneDrive/Pictures/Scans/Scan_20210315.pdf
Looks like all these companies have as their principle address MyMD's suite at Johns Hopkins.
I'm flabbergasted, so don't know what to say!
https://www.flcompany.info/companies/P21000016093/
Here is yet another new FL company whose principle address is MyMD's suite at Johns Hopkins
https://www.flcompany.info/companies/P21000016093/
Everyone seen this -
https://www.mymd.com/pipeline/mymd-1
At the risk of repetition just noticed that a new company started in 2021 by Jonnie and associates, named Nemo Life Sciences is located in the same Johns Hopkins Life Sciences building as MyMD Pharma. Noticed also that its suite number ended in .5 which indicates it may be in the same suite as MyMD.
Also found this read on NEMO.
While we can rule out Covid-19 as the delay involved in this merger, the fact that the S-4 submitted to the SEC explaining the merger is 630 pages long, just might indicate how complex this merger is!
On another note, MyMD Pharma, just before the merger takes place, will issue nearly 34 million of its shares to shareholders of Supera Pharma, thereby acquiring Supera. Supera was begun by Jonnie R Williams and associates.
That's right, but oh so many questions!